Clinical Trials in Barnaul, Russia
14 recruiting
Showing 1–19 of 19 trials
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
Breast Cancer
Novartis Pharmaceuticals2,766 enrolled37 locationsNCT06930859
Recruiting
Not Applicable
Efferon LPS Hemoadsorption in Cardiac Surgery Patients
Cardiac DiseaseMultiple Organ Dysfunction Syndrome
Efferon JSC60 enrolled3 locationsNCT07532174
Recruiting
Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)
Severe Asthma
AstraZeneca5,000 enrolled37 locationsNCT06472310
Recruiting
Phase 4
Secukinumab Open Label Roll-over Extension Protocol
Autoimmunity, Inflammation
Novartis Pharmaceuticals1,000 enrolled167 locationsNCT04638647
Recruiting
An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation
Endometrial Cancer
AstraZeneca500 enrolled21 locationsNCT07041606
Recruiting
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
Prostate Cancer
AstraZeneca400 enrolled18 locationsNCT07052578
Recruiting
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
Bladder Cancer
AstraZeneca600 enrolled19 locationsNCT07038928
Recruiting
The Surveillance Clinical Study of Rickettsiosis
Rickettsiosis
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation2,000 enrolled24 locationsNCT06162975
Recruiting
CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia
Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
AstraZeneca2,000 enrolled41 locationsNCT05887011
Recruiting
Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation
Prostate Cancer
AstraZeneca400 enrolled17 locationsNCT07146113
Recruiting
Phase 3
Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism
Pulmonary Embolism
Supergene, LLC486 enrolled24 locationsNCT06362746
Recruiting
Phase 2
Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis
Ulcerative Colitis (UC)
Biocad198 enrolled20 locationsNCT07080034
Recruiting
Phase 2
Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease
Crohn's Disease (CD)
Biocad204 enrolled20 locationsNCT07078994
Recruiting
Phase 2
BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
Biocad124 enrolled47 locationsNCT07108309
Recruiting
Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
Von Willebrand Disease
Baxalta now part of Shire31 enrolled46 locationsNCT02932618
Recruiting
Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice
Obstructive JaundiceGallstone Disease
POLYSAN Scientific & Technological Pharmaceutical Company286 enrolled9 locationsNCT05928286
Recruiting
Phase 2Phase 3
Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases
Lung Diseases, Interstitial
R-Pharm International, LLC138 enrolled33 locationsNCT06440746
Recruiting
Phase 3
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Chronic Myeloid Leukemia, Chronic PhaseCML, Chronic PhaseCML, Refractory+1 more
Il-Yang Pharm. Co., Ltd.173 enrolled18 locationsNCT03459534